12 June 2026 • Alpha Insights Sector Research
Top 50 Healthcare Stocks Ranked: Pharma, Biotech, and MedTech Scored for Quality and Ethics
Healthcare has become the quiet defensive rotation of mid-2026. With the Iran crisis driving capital away from risk assets, ageing demographics accelerating structural demand, and artificial intelligence reshaping drug discovery timelines, we have scored every healthcare name in our universe using a dual-pillar system that measures both classical opportunity and ethical-trading/” style=”color:#D8AF44;text-decoration:underline” title=”Ethical Trading”>ethical alignment. These are the 50 names that matter right now.
What You Will Find in This Article
- Full ranked table of 50 healthcare stocks by blended Ethical + Opportunity Score (TOS)
- Deep-dive analysis of the top 10 names
- Ethical screening breakdown: how many pass, how many flag
- Interactive chart of top 20 scores
- Links to every ticker page and our live Sector Rankings tool
Why Healthcare Stocks Demand Attention Right Now
Three forces are converging on healthcare equities in a way we have not seen for years. First, the geopolitical backdrop. The Iran crisis and Hormuz disruption have triggered a classic flight to defensive quality. Healthcare, alongside utilities and consumer staples, is absorbing capital from investors de-risking cyclical exposure. When crude spikes above $84 and global trade routes face existential uncertainty, the sector that treats cancer and manages chronic disease does not miss a beat.
Second, demographics. The global population aged 65 and over will surpass 1 billion before 2030. That is not a forecast — it is arithmetic. Every additional year of life expectancy translates into incremental demand for pharmaceuticals, diagnostics, medical devices, and managed care. This is the only sector where demand growth is biologically guaranteed.
Third, artificial intelligence is compressing drug discovery timelines from a decade to years. Companies like Incyte, Regeneron, and Bristol Myers Squibb are deploying machine-learning models that screen billions of molecular candidates in weeks rather than months. The cost of bringing a drug from laboratory to patient is falling, and the first movers in AI-assisted discovery will capture disproportionate returns. For investors, the challenge is separating signal from noise: which healthcare names combine genuine opportunity with clean governance and responsible operations? Our dual-pillar scoring system answers precisely that question.
How the Dual-Pillar Scoring Works
Every stock in our universe receives two independent scores:
Classical Pillar (0-100)
Measures opportunity through momentum, relative strength, valuation, earnings quality, and growth trajectory. A stock scoring 80+ here is firing on all classical cylinders.
Ethical Pillar (0-100)
Screens for governance, controversial operations, sanctioned exposure, environmental violations, and business ethics. Higher scores indicate cleaner operations and better alignment with responsible investment principles.
The Blended TOS (Total Opportunity Score) combines both pillars into a single rank. Stocks land in one of four tiers:
- PLATINUM — TOS 85+ — Exceptional across both pillars
- GOLD — TOS 70–84.99 — Strong opportunity with solid ethics
- SILVER — TOS 55–69.99 — Moderate opportunity, some flags
- BRONZE — TOS 40–54.99 — Lower conviction or ethical concerns
Top 20 Healthcare Stocks by Blended Score
Ethical Screening Breakdown
41
Ethical Score 50+
Pass basic ethical threshold
16
Ethical Score 70+
Strong ethical alignment
2
Ethical Score Below 30
Significant ethical flags
Of the 50 healthcare stocks in our ranked universe, 41 clear the basic ethical threshold of 50. Sixteen names score above 70, indicating strong governance and responsible operations — a notably higher proportion than we see in energy. Two names — EGRX (Eagle Pharmaceuticals, 29.41) and AMS (American Shared Hospital Services, 29.91) — carry significant ethical flags that investors should examine before allocating.
The standout ethical performers are Check-Cap (MBAI) at 98.29, Enlivex (ENLV) at 96.63, Eton Pharmaceuticals (ETON) at 92.45, and Fennec Pharmaceuticals (FENC) at 89.78. These are predominantly smaller biotech names where focused therapeutic missions and clean governance structures naturally produce high ethical scores. The sector-wide takeaway is clear: healthcare has a structurally higher ethical floor than energy, reflecting less operational controversy and fewer sanctioned-jurisdiction exposures.
Top 10 Deep Dive
87.53
Blended TOS
Ethical: 86.58
Incyte is the only healthcare name in our universe to break into Platinum territory, and it does so with remarkable balance. The ethical pillar at 86.58 places it among the cleanest operators in the entire sector, while the classical score of 78.25 confirms genuine opportunity in the stock. Incyte’s focus on oncology and inflammation — with Jakafi as its commercial anchor and a deepening pipeline in dermatology — gives it defensive revenue streams that hold up regardless of macro conditions. In a market rotating into quality healthcare amid geopolitical uncertainty, this is the name that ticks every box. The $19.7B market cap is liquid enough for institutional allocations without being so large that growth becomes impossible.
81.80
Blended TOS
Ethical: 48.85
CorMedix is a classical-pillar story. The highest classical score among our top five at 82.28 reflects strong momentum and earnings trajectory, driven by the commercial ramp of DefenCath — its FDA-approved catheter lock solution for bloodstream infections. The ethical score of 48.85 sits just below the 50 threshold, which is worth noting for mandate-constrained investors. At $655.9M market cap, this is a small-cap name with single-product concentration risk, but the opportunity scoring says the market is rewarding that product aggressively right now. A name to watch, not necessarily to buy on ethics alone.
79.92
Blended TOS
Ethical: 58.78
Universal Health Services runs acute care hospitals and behavioural health facilities across the United States. The classical pillar at 81.48 reflects robust earnings growth and occupancy rates that have exceeded pre-pandemic levels. UHS is a direct beneficiary of the behavioural health crisis — demand for mental health and substance abuse treatment has surged, and UHS operates one of the largest networks of inpatient behavioural facilities in the country. The ethical score of 58.78 reflects the inherent complexity of hospital operations: billing practices, staffing, and regulatory compliance all create ethical surface area. At $10.2B market cap, UHS offers a mid-cap entry point into a structural demand story.
78.27
Blended TOS
Ethical: 89.78
Fennec is the mirror image of CorMedix: here, the ethical pillar does the heavy lifting. At 89.78, Fennec carries one of the highest ethical scores in our entire healthcare universe. The company’s sole focus is PEDMARK, a treatment that prevents hearing loss in children receiving chemotherapy — a mission-driven product with undeniable social value. The classical score of 56.25 is modest, reflecting the reality of a $339.8M market cap company with a single commercialised product. But for ethical mandate investors, Fennec represents one of the purest alignment plays in healthcare: a company whose entire existence addresses paediatric suffering.
78.15
Blended TOS
Ethical: 39.73
Regeneron is the big pharma name that divides our two pillars most sharply. The classical score of 80.27 is among the highest in the sector, reflecting Dupixent’s blockbuster trajectory, an expanding oncology pipeline, and consistently strong free cash flow generation. Yet the ethical pillar at 39.73 flags governance concerns that ethical investors cannot overlook. Like Petrobras in our energy rankings, Regeneron presents a genuine investor dilemma: the opportunity is real, the ethics are complicated. Our blended scoring handles this by tempering the overall rank, but for classical-only investors, REGN at $73.2B market cap remains one of the most compelling large-cap pharma names in the universe.
77.53
Blended TOS
Ethical: 58.64
DaVita is the dominant kidney dialysis provider in the United States, and that dominance translates into predictable recurring revenue. Patients requiring dialysis need treatment three times a week — every week, without exception. That makes DaVita’s revenue stream as close to subscription-model as healthcare gets. The classical score of 68.44 reflects solid operating performance, while the ethical pillar at 58.64 captures the regulatory scrutiny that comes with being a near-monopoly in an essential medical service. Warren Buffett’s Berkshire Hathaway remains a major shareholder, which tells you something about the durability of the business model.
76.91
Blended TOS
Ethical: 57.79
Becton Dickinson is the MedTech infrastructure play. Syringes, needles, specimen collection systems, diagnostic instruments — the consumables that hospitals cannot function without. BDX does not make headlines because its products are not glamorous, but that is precisely the point. In a crisis environment, demand for basic medical supplies is inelastic. The classical score of 67.46 reflects steady execution, while the ethical pillar at 57.79 captures the complexity of global medical device distribution. At $41.2B market cap, BDX offers the kind of boring, reliable healthcare exposure that portfolio managers quietly accumulate during volatile periods.
76.88
Blended TOS
Ethical: 73.15
Cigna stands out as the most balanced name in the top 10. Both pillars score above 72, meaning there is no trade-off — you get solid opportunity and solid ethics in the same ticket. The Evernorth Health Services division has transformed Cigna from a pure insurer into an integrated health services company with pharmacy benefit management, speciality pharmacy, and care delivery. The ethical score of 73.15 is the highest among the large-cap names in our top 10, reflecting relatively clean governance and responsible operations. At $76.0B market cap, Cigna offers deep liquidity for any allocation size.
76.44
Blended TOS
Ethical: 58.43
Bristol Myers Squibb is navigating the Opdivo and Eliquis patent cliff while simultaneously building a next-generation pipeline through acquisitions and internal R&D. The classical score of 66.11 reflects this transition period: revenue is still substantial at $114.7B market cap, but the market is pricing in patent expiration headwinds. The ethical pillar at 58.43 is solid for a company of this complexity. For income investors, BMY’s dividend yield remains attractive, and the pipeline — particularly in immunology and cardiovascular — offers optionality that the current share price may be undervaluing. This is a large-cap pharma name where patience may be rewarded.
75.90
Blended TOS
Ethical: 92.45
Eton Pharmaceuticals rounds out the top 10 with the highest ethical score in the group at 92.45. The company focuses on innovative pharmaceutical products for rare and underserved conditions — exactly the kind of mission that produces high ethical alignment. The classical pillar at 49.80 is below 50, which tells us the opportunity metrics are not yet firing on all cylinders. This is a small-cap name at $814.6M where the ethical case is ahead of the opportunity case. For investors with a longer time horizon and an ethical mandate, ETON offers rare alignment between what you own and what the company does.
Full Rankings: 50 Healthcare Stocks by Blended TOS
| # | Ticker | Company | Price | Mkt Cap | Classical | Ethical | Blended | Tier |
|---|---|---|---|---|---|---|---|---|
| 1 | INCY | Incyte | $102.38 | $19.7B | 78.25 | 86.58 | 87.53 | PLATINUM |
| 2 | CRMD | CorMedix Inc. | $8.36 | $655.9M | 82.28 | 48.85 | 81.80 | GOLD |
| 3 | UHS | Universal Health Services | $145.17 | $10.2B | 81.48 | 58.78 | 79.92 | GOLD |
| 4 | FENC | Fennec Pharmaceuticals Inc. | $8.70 | $339.8M | 56.25 | 89.78 | 78.27 | GOLD |
| 5 | REGN | Regeneron Pharmaceuticals | $635.45 | $73.2B | 80.27 | 39.73 | 78.15 | GOLD |
| 6 | DVA | DaVita | $192.16 | $12.8B | 68.44 | 58.64 | 77.53 | GOLD |
| 7 | BDX | Becton Dickinson | $151.16 | $41.2B | 67.46 | 57.79 | 76.91 | GOLD |
| 8 | CI | Cigna | $289.48 | $76.0B | 72.14 | 73.15 | 76.88 | GOLD |
| 9 | BMY | Bristol Myers Squibb | $57.27 | $114.7B | 66.11 | 58.43 | 76.44 | GOLD |
| 10 | ETON | Eton Pharmaceuticals, Inc. | $29.13 | $814.6M | 49.80 | 92.45 | 75.90 | GOLD |
| 11 | SNY | Sanofi SA | $45.02 | $102.4B | 78.08 | 72.97 | 75.85 | GOLD |
| 12 | GILD | Gilead Sciences | $129.16 | $163.1B | 76.47 | 47.36 | 75.69 | GOLD |
| 13 | ZTS | Zoetis | $79.44 | $34.7B | 65.22 | 53.04 | 74.96 | GOLD |
| 14 | PFE | Pfizer | $26.04 | $144.3B | 78.67 | 55.42 | 74.35 | GOLD |
| 15 | IQV | IQVIA | $183.45 | $29.8B | 67.03 | 55.91 | 74.25 | GOLD |
| 16 | HCA | HCA Healthcare | $372.13 | $96.5B | 61.16 | 57.18 | 73.96 | GOLD |
| 17 | NVO | Novo Nordisk A/S | $42.96 | $197.0B | 67.60 | 59.50 | 73.82 | GOLD |
| 18 | SOLV | Solventum | $81.01 | $12.7B | 60.02 | 58.82 | 73.77 | GOLD |
| 19 | MRK | Merck & Co. | $120.79 | $275.1B | 63.60 | 55.10 | 73.50 | GOLD |
| 20 | LH | Labcorp | $265.15 | $20.8B | 67.47 | 58.08 | 73.39 | GOLD |
| 21 | VTRS | Viatris | $15.88 | $20.0B | 58.88 | 56.87 | 72.87 | GOLD |
| 22 | KMDA | Kamada Ltd. | $7.17 | $451.5M | 66.75 | 82.02 | 72.38 | GOLD |
| 23 | MAIA | MAIA Biotechnology, Inc. | $1.36 | $78.4M | 51.56 | 70.59 | 72.32 | GOLD |
| 24 | PBSV | Pharma-Bio Serv, Inc. | $0.53 | $12.1M | 50.00 | 70.59 | 71.62 | GOLD |
| 25 | GSK | GSK PLC (GlaxoSmithKline) | $51.52 | $98.3B | 71.47 | 70.00 | 71.54 | GOLD |
| 26 | PHR | Phreesia, Inc. | $9.54 | $543.0M | 52.03 | 64.62 | 71.34 | GOLD |
| 27 | AVAH | Aveanna Healthcare Holdings Inc. | $6.68 | $1.6B | 62.80 | 47.95 | 71.23 | GOLD |
| 28 | PODD | Insulet Corporation | $153.22 | $10.3B | 66.10 | 55.34 | 70.87 | GOLD |
| 29 | DOCS | Doximity, Inc. | $20.59 | $3.5B | 86.50 | 84.76 | 70.58 | GOLD |
| 30 | BAX | Baxter International | $19.38 | $9.3B | 53.27 | 55.65 | 70.10 | GOLD |
| 31 | ZBH | Zimmer Biomet | $87.33 | $16.1B | 74.20 | 59.37 | 69.37 | SILVER |
| 32 | TXMD | TherapeuticsMD, Inc. | $1.99 | $24.5M | 54.84 | 46.06 | 68.89 | SILVER |
| 33 | AMGN | Amgen | $349.58 | $179.1B | 62.95 | 58.82 | 68.79 | SILVER |
| 34 | VEEV | Veeva Systems | $172.61 | $27.1B | 66.73 | 39.84 | 68.66 | SILVER |
| 35 | WAT | Waters Corporation | $365.36 | $32.6B | 65.34 | 59.86 | 66.62 | SILVER |
| 36 | EGRX | Eagle Pharmaceuticals, Inc. | $0.60 | $3.3M | 56.31 | 29.41 | 66.22 | SILVER |
| 37 | DGX | Quest Diagnostics | $200.29 | $20.7B | 68.88 | 57.38 | 66.10 | SILVER |
| 38 | ABBV | AbbVie | $227.23 | $356.5B | 51.44 | 56.09 | 64.95 | SILVER |
| 39 | CGEN | Compugen Ltd. | $2.10 | $260.0M | 73.75 | 69.17 | 64.52 | SILVER |
| 40 | ENLV | Enlivex Ltd. | $0.71 | $175.9M | 60.31 | 96.63 | 63.97 | SILVER |
| 41 | MCK | McKesson Corporation | $775.66 | $91.3B | 70.46 | 87.44 | 63.75 | SILVER |
| 42 | CRL | Charles River Laboratories | $181.34 | $8.6B | 51.52 | 55.51 | 63.69 | SILVER |
| 43 | ABUS | Arbutus Biopharma Corporation | $4.25 | $837.6M | 73.75 | 89.80 | 63.40 | SILVER |
| 44 | BIIB | Biogen | $195.34 | $28.7B | 76.95 | 63.38 | 62.14 | SILVER |
| 45 | AMS | American Shared Hospital Services | $1.33 | $10.7M | 46.20 | 29.91 | 61.77 | SILVER |
| 46 | CPRX | Catalyst Pharmaceuticals, Inc. | $31.27 | $3.8B | 78.84 | 70.00 | 61.73 | SILVER |
| 47 | MBAI | Check-Cap Ltd. | $1.38 | $12.5M | 66.25 | 98.29 | 61.72 | SILVER |
| 48 | GEHC | GE HealthCare | $64.67 | $27.9B | 77.79 | 62.61 | 61.46 | SILVER |
| 49 | ICLR | ICON Public Limited Company | $149.45 | $9.1B | 59.47 | 54.25 | 60.84 | SILVER |
| 50 | BWAY | BrainsWay Ltd. | $13.89 | $601.8M | 59.17 | 89.20 | 60.67 | SILVER |
Five Key Themes from the Rankings
1. Big Pharma Dominates the Middle, Not the Top
Merck, Pfizer, AbbVie, Amgen, and Bristol Myers Squibb all appear in our top 50, but none breaks into the top five. This is not because they are poor investments — far from it. These are companies with $100B+ market caps, massive revenue bases, and deep pipelines. But the dual-pillar scoring penalises names with moderate ethical scores and rewards those with exceptional alignment on one or both pillars. The message is clear: big pharma offers safety and scale, but smaller names with cleaner ethical profiles can outrank them in our system.
2. Small Biotechs Lead on Ethics
MBAI (98.29), ENLV (96.63), ETON (92.45), FENC (89.78), ABUS (89.80), and BWAY (89.20) — six of the top ethical scores belong to companies under $1B market cap. Smaller biotech companies focused on single therapeutic areas tend to have fewer ethical trip-wires: no diversified operations across controversial jurisdictions, no complex supply chains, no legacy governance issues. For ethical mandate investors, the small-cap biotech space is where alignment lives.
3. The Obesity and GLP-1 Theme
Novo Nordisk sits at number 17 with a blended score of 73.82. The GLP-1 revolution — Ozempic, Wegovy, and the pipeline behind them — has redefined what healthcare can be worth. But NVO’s ethical score of 59.50 reflects the complexity of pricing access and global distribution of these drugs. The market is watching how the obesity treatment category matures, and our scoring captures both the undeniable opportunity and the ethical questions around pricing essential medications at scale.
4. Healthcare IT Is a Hidden Gem
Doximity (DOCS) at number 29 is one of the most interesting names in the table. With a classical score of 86.50 and an ethical score of 84.76, it scores higher than almost every name on both individual pillars — yet its blended TOS of 70.58 places it mid-table. This is a healthcare platform play: the “LinkedIn for doctors” with high margins, recurring revenue, and no direct patient care liability. Veeva Systems (VEEV) at number 34 tells a similar story on the enterprise software side. Healthcare IT may be the highest-quality sub-sector for dual-pillar investors.
5. Defensive Rotation Is Already Underway
The fact that 30 of our 50 names sit in Gold or Platinum territory tells us something about healthcare’s positioning in mid-2026. Capital is flowing into the sector not because of a single catalyst, but because of the convergence of three structural forces: Iran-driven risk-off rotation, demographic inevitability, and AI-accelerated drug discovery. When the largest company in the table — AbbVie at $356.5B — scores Silver while Incyte at $19.7B takes Platinum, it tells us that quality and ethics are being rewarded, not just size.
How to Use These Rankings
This table is a starting point, not a trade instruction. We use it in three ways:
- Screen for conviction. Platinum and Gold tier names represent the highest-conviction overlap between opportunity and ethics. Start your research there.
- Filter by your mandate. If ethical screening is a hard requirement, sort by the ethical pillar and eliminate anything below your threshold. If you are mandate-agnostic, the classical pillar alone tells you where the opportunity lives.
- Explore individual names. Every ticker in this table links to its dedicated analysis page at
/ticker/{SYMBOL}/where you will find the full scoring breakdown, historical trend, and peer comparison.
For the fully interactive, filterable version of these rankings with real-time updates, visit our Healthcare Sector Rankings tool.
Methodology Notes
Scores are calculated from the latest snapshot in our quantitative database. The classical pillar draws on momentum, relative strength, valuation, earnings quality, and growth trajectory. The ethical pillar evaluates governance, controversial operations, sanctioned exposure, environmental compliance, and business ethics. Both pillars are scored 0-100 and combined into the blended TOS using a weighting scheme that respects both dimensions without allowing one to dominate.
Market capitalisation and price data reflect the most recent trading session. Tier assignments (Platinum, Gold, Silver, Bronze) are based on the blended TOS and update automatically when scores refresh.
This analysis covers 50 healthcare-sector stocks from our scored universe. For rankings across all sectors, visit our full Sector Rankings page.
Disclaimer
This article is for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy or sell any security. Scores and rankings reflect quantitative analysis at a point in time and may change. Past performance is not indicative of future results. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions. Alpha Insights and its contributors may hold positions in securities mentioned.
Deepen Your Understanding
Related articles from the Titan Protect Foundry: